Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000868278-25-000007
Filing Date
2025-05-20
Accepted
2025-05-20 16:06:42
Documents
69
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q prph-20250331.htm   iXBRL 10-Q 973122
2 EX-31.1 prph-20250331xexx311.htm EX-31.1 10968
3 EX-32.1 prph-20250331xexx321.htm EX-32.1 5291
  Complete submission text file 0000868278-25-000007.txt   7280593

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20250331.xsd EX-101.SCH 57611
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT prph-20250331_cal.xml EX-101.CAL 123803
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prph-20250331_def.xml EX-101.DEF 299749
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20250331_lab.xml EX-101.LAB 805465
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20250331_pre.xml EX-101.PRE 535182
72 EXTRACTED XBRL INSTANCE DOCUMENT prph-20250331_htm.xml XML 846955
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-21617 | Film No.: 25968769
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)